人急性髓系白血病细胞MUTZ-3

  细胞系     |      2022-12-11 16:22
品牌自营品牌货号BFN60808560
规格T25培养瓶x1 1.5ml冻存管x2供货周期现货
主要用途仅供科研应用领域医疗卫生,生物产业

细胞名称

人急性髓系白血病细MUTZ-3

img1

货物编码

BFN60808560

产品规格

T25培养x1

1.5ml冻存x2

细胞数量

1x10^6

1x10^6

保存温度

37

-198

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科 2

培养体系

DMEM+10%FBS+1%三抗

培养温度

37

二氧化碳浓度

5%

简介

人急性髓系白血病细MUTZ-329岁男性病人外周血。该细胞源DSMZ

注释

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: LL-100 blood cancer cell line panel.

Characteristics: Contains both CD34+ stem cell and CD14+ monocyte/macrophage cell populations and can thus be considered as a hematopoietic progenitor/stem cell line.

Doubling time: ~110 hours (DSMZ); 90-110 hours, in presence of supernatant of 5637 (CVCL_0126) cells (PubMed=8667638).

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: H3K79me1 ChIP-seq epigenome analysis.

Omics: Transcriptome analysis.

Derived from sampling site: Peripheral blood.

基因突变

KRAS p.Gly10_Ala11insGly (c.31_32insGAG) (CCLE).

HLA信息

/

STR信息

Amelogenin X,Y

CSF1PO 12,13

D5S818 12,13

D7S820 10,12

D13S317 8,12

D16S539 12

TH01 6,9.3

TPOX 8,11

vWA 14,16

参考文献

Patent=US8455253

Goletz S., Scheper R.J., Masterson A.J., Pinedo H.M.

Differentiation of MUTZ-3 cells to produce effective dendritic cells.

Patent number US8455253, 04-Jun-2013

PubMed=30285677; DOI=10.1186/s12885-018-4840-5

Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

BMC Cancer 18:940-940(2018)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x

Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.

The LL-100 panel: 100 cell lines for blood cancer studies.

Sci. Rep. 9:8218-8218(2019)

青旗(上海)生物技术发展有限公司,总部位于上海浦东新区,依托本地高校资源,逐步发展成为以生物技术为主的研发、生产、培训为一体的综合化产业平台,在标准化细胞库建立及细胞药物前端模型方面成果显著。公司生产经营原代细胞、细胞系、ELISA试剂盒、感受态细胞和HPLC检测等科研产品与服务。我们秉承对用户负责的态度,以对科研的高度严谨,以严格的质量控制,为广大生物医学科研用户提供更优质的服务!